RecruitingNCT07018037

Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma

Pilot Study to Describe the Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma


Sponsor

Regina Elena Cancer Institute

Enrollment

20 participants

Start Date

Jan 29, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Patients over 18 years of age;
  • Histological diagnosis of clear cell renal cell carcinoma;
  • Evidence of advanced or metastatic disease;
  • Patients diagnosed with metastatic clear cell renal cell carcinoma about to start first-line immunotherapy (ICI + ICI or ICI + TKI);
  • Patients able to comply with the study procedures.
  • Patients who give written informed consent personally or through a witness (study participation and data processing), before any study-specific procedure is started.

Exclusion Criteria5

  • Previous neoplasms;
  • Previous antineoplastic treatments;
  • Previous steroid treatments;
  • Active viral infections (e.g., HCV, HIV, etc.);
  • Lack of autonomy in adhering to study procedures.

Locations(1)

"Regina Elena" National Cancer Institute

Rome, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07018037


Related Trials